
    
      Patients will receive continuous treatment with oral everolimus 10 mg once daily. Study drug
      will be self-administered orally (two 5 mg tablets) daily in a fasting state or with a light
      fat-free meal. Each cycle will be considered as 21 days of treatment; safety was assessed
      every 21 days. Tumor assessement will be done every two cycles. Treatment should be
      administered until documented disease progression, unacceptable toxicity, or patient refusal.
    
  